Marta Palop-Cervera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marta Palop-Cervera has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
A. de Diego Damiá
Servicio de Neumología, Consorcio Hospital General Universitario, Valencia, España
1 shared publication- Alicia Padilla-Galo
Hospital Universitario Virgen de la Victoria, Malaga, Spain
1 shared publication - Carlos Martínez-Rivera
Hospital Universitari Germans Trias I Pujol, Badalona, Spain
1 shared publication - Carmen Paula Barragán
Medical Department, AstraZeneca Farmacéutica S.A, Calle del Puerto de Somport, 21-23, 28050 Madrid, Spain
1 shared publication - Elisa Luzon
Medical Department, AstraZeneca Farmacéutica, 28050 Madrid, Spain
1 shared publication - Ernesto Cortés-Castell
Department of Pharmacology, Pediatrics and Organic Chemistry, Miguel Hernández University of Elche, 03550 Elche, Spain
1 shared publication
Latest Publications
- Open Access
- 7 November 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (22) , 7900
ORBE II Study: Clinical Characteristics and Outcomes After Treatment with Benralizumab According to Airflow Obstruction Status and Smoking Habit
Background/Objectives: Evidence on the use of biologics in severe eosinophilic asthma (SEA) associated with persistent airflow obstruction (PAO) status and smoking habits is scarce. As these factors could potentially impact real-world benralizumab clinical effects, this study was conceived to provide a deeper understanding of these specific patient subgroups. Methods: This observational, retrospective ORBE II study (NCT04648839) involved 204 adults with uncontrolled SEA treated with benralizumab in Spain. In this analysis, patients were categorized by baseline PAO status (PAO− or PAO+) and smoking habit (SMK− or SMK+) to assess baseline characteristics and clinical outcomes after one year of follow-up. The impact of smoking on PAO+ patients was also analyzed. Results: This analysis showed that 75.6% of patients had PAO and 36.9% were former/current smokers. After benralizumab, both PAO subgroups showed substantial improvement, with higher proportions of PAO+ patients achieving prespecified clinical objectives. Benralizumab benefited patients regardless of their smoking habit, though patients who had never smoked exhibited slightly fewer exacerbations, greater improvements in ACT scores, and a higher proportion achieved a ≥100 mL increase in pre-BD FEV1. An analysis of the impact of smoking on the PAO+ subgroup showed that while a similar proportion of patients were able to eliminate exacerbations and discontinue OCS use, higher percentages of PAO+SMK− patients achieved an ACT score ≥ 20 and a ≥100 mL increase in pre-BD FEV1. Conclusions: PAO is common among patients included in ORBE II, and a considerable proportion are former/current smokers. This study showed that clinical outcomes improved after benralizumab initiation regardless of these factors, highlighting its potential as a valuable therapeutic option for managing SEA. These findings also emphasize the need for further real-world evidence to optimize treatment strategies for diverse patient subgroups.
- 7 November 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (22) , 7900
Open AccessORBE II Study: Clinical Characteristics and Outcomes After Treatment with Benralizumab According to Airflow Obstruction Status and Smoking Habit
Background/Objectives: Evidence on the use of biologics in severe eosinophilic asthma (SEA) associated with persistent airflow obstruction (PAO) status and smoking habits is scarce. As these factors could potentially impact real-world benralizumab clinical effects, this study was conceived to provide a deeper understanding of these specific patient subgroups. Methods: This observational, retrospective ORBE II study (NCT04648839) involved 204 adults with uncontrolled SEA treated with benralizumab in Spain. In this analysis, patients were categorized by baseline PAO status (PAO− or PAO+) and smoking habit (SMK− or SMK+) to assess baseline characteristics and clinical outcomes after one year of follow-up. The impact of smoking on PAO+ patients was also analyzed. Results: This analysis showed that 75.6% of patients had PAO and 36.9% were former/current smokers. After benralizumab, both PAO subgroups showed substantial improvement, with higher proportions of PAO+ patients achieving prespecified clinical objectives. Benralizumab benefited patients regardless of their smoking habit, though patients who had never smoked exhibited slightly fewer exacerbations, greater improvements in ACT scores, and a higher proportion achieved a ≥100 mL increase in pre-BD FEV1. An analysis of the impact of smoking on the PAO+ subgroup showed that while a similar proportion of patients were able to eliminate exacerbations and discontinue OCS use, higher percentages of PAO+SMK− patients achieved an ACT score ≥ 20 and a ≥100 mL increase in pre-BD FEV1. Conclusions: PAO is common among patients included in ORBE II, and a considerable proportion are former/current smokers. This study showed that clinical outcomes improved after benralizumab initiation regardless of these factors, highlighting its potential as a valuable therapeutic option for managing SEA. These findings also emphasize the need for further real-world evidence to optimize treatment strategies for diverse patient subgroups.
- Open Access
Effect of an Immune-Boosting, Antioxidant and Anti-Inflammatory Food Supplement in Hospitalized COVID-19 Patients: A Prospective Randomized Pilot Study
Background: COVID-19 disease is a serious global health problem. Few treatments have been shown to reduce mortality and accelerate time to recovery. The aim of this study was to evaluate the potential effect of a food supplement (probiotics, prebiotics, vitamin D, zinc and selenium) in patients admitted with COVID-19. Methods: A prospective randomized non-blinded clinical trial was conducted in a sample of 162 hospitalized patients diagnosed with COVID-19 recruited over eight months. All patients received standard treatment, but the intervention group (n = 67) was given one food supplement stick daily during their admission. After collecting the study variables, a statistical analysis was performed comparing the intervention and control groups and a multivariate analysis controlling for variables that could act as confounding factors. Results: ROC curve analysis with an area under the curve (AUC) value of 0.840 (p < 0.001; 95%CI: 0.741–0.939) of the food supplement administration vs. recovery indicated good predictive ability. Moreover, the intervention group had a shorter duration of digestive symptoms compared with the control group: 2.6 ± 1.3 vs. 4.3 ± 2.2 days (p = 0.001); patients with non-severe disease on chest X-ray had shorter hospital stays: 8.1 ± 3.9 vs. 11.6 ± 7.4 days (p = 0.007). Conclusions: In this trial, the administration of a food supplement (Gasteel Plus®) was shown to be a protective factor in the group of patients with severe COVID-19 and allowed early recovery from digestive symptoms and a shorter hospital stay in patients with a normal–mild–moderate chest X-ray at admission (ClinicalTrials.gov number, NCT04666116).
Open AccessEffect of an Immune-Boosting, Antioxidant and Anti-Inflammatory Food Supplement in Hospitalized COVID-19 Patients: A Prospective Randomized Pilot Study
Background: COVID-19 disease is a serious global health problem. Few treatments have been shown to reduce mortality and accelerate time to recovery. The aim of this study was to evaluate the potential effect of a food supplement (probiotics, prebiotics, vitamin D, zinc and selenium) in patients admitted with COVID-19. Methods: A prospective randomized non-blinded clinical trial was conducted in a sample of 162 hospitalized patients diagnosed with COVID-19 recruited over eight months. All patients received standard treatment, but the intervention group (n = 67) was given one food supplement stick daily during their admission. After collecting the study variables, a statistical analysis was performed comparing the intervention and control groups and a multivariate analysis controlling for variables that could act as confounding factors. Results: ROC curve analysis with an area under the curve (AUC) value of 0.840 (p < 0.001; 95%CI: 0.741–0.939) of the food supplement administration vs. recovery indicated good predictive ability. Moreover, the intervention group had a shorter duration of digestive symptoms compared with the control group: 2.6 ± 1.3 vs. 4.3 ± 2.2 days (p = 0.001); patients with non-severe disease on chest X-ray had shorter hospital stays: 8.1 ± 3.9 vs. 11.6 ± 7.4 days (p = 0.007). Conclusions: In this trial, the administration of a food supplement (Gasteel Plus®) was shown to be a protective factor in the group of patients with severe COVID-19 and allowed early recovery from digestive symptoms and a shorter hospital stay in patients with a normal–mild–moderate chest X-ray at admission (ClinicalTrials.gov number, NCT04666116).
- 31 August 2010
- Published by Elsevier in Revista Clínica Española
- Vol. 210 (7) , 323-331
Factores predictores de mortalidad en pacientes con enfermedad pulmonar obstructiva crónica y exacerbaciones frecuentes
- 31 August 2010
- Published by Elsevier in Revista Clínica Española
- Vol. 210 (7) , 323-331
Factores predictores de mortalidad en pacientes con enfermedad pulmonar obstructiva crónica y exacerbaciones frecuentes